每经记者｜林姿辰 每经编辑｜董兴生 2025年10月10日是第34个世界精神卫生日，"人人享有心理健康服务"的活动主题背后，是我国精神卫生 领域面临的日益严峻的挑战。 数据显示，我国精神分裂症患者因依从性不高治疗中断率达75%，出院后1年内复发率达77%，2年内攀 升至90%，每次复发直接医疗成本激增4倍。 因此，如何避免患者漏服药，提高患者治疗依从性是改善患者功能预后的关键环节。 最新指南强调长效针剂作用，而目前临床使用率尚不足5% 今年9月12日，《中国精神分裂症防治指南（2025版）》正式发布，是近10年来首次更新。作为该版指 南的副主编，刘登堂表示，这次更新有两个核心变化，一是撰写方式从传统"教科书或综述式"，转 向"临床问题+推荐意见+循证证据导向"；二是在维持治疗部分，明确强调了抗精神病药物长效针剂的 临床使用价值，建议在尊重患者意愿的情况下，早期启用长效针剂。 长效针剂对比口服药物，成分一致、剂型不同，能显著降低患者用药频率，提升治疗依从性。据记者梳 理，目前国内已有几款长效针剂获批，比如绿叶制药的利培酮微球、强生的棕榈帕利哌酮酯注射液等。 获批时间最近的，则是丽珠医药研发的注射用阿立哌唑微球， ...

Teva Pharmaceutical Industries Conference Call Summary Company Overview - **Company**: Teva Pharmaceutical Industries (NYSE: TEVA) - **Focus**: Development of Elanzapin LAI for the treatment of schizophrenia Key Industry Insights - **Schizophrenia**: A complex and progressive mental illness characterized by both positive and negative symptoms, cognitive implications, and mood disturbances, significantly impacting patients' quality of life [4][10] - **Market Opportunity**: High unmet needs in schizophrenia treatment, with a significant number of patients in both the U.S. and EU, particularly favoring long-acting injectables (LAIs) [12][10] Core Product Insights - **Elanzapin LAI**: A new formulation designed to prevent Post-Injection Delirium and Sedation Syndrome (PDSS), which has been a barrier to the use of Elanzapin in LAI form [5][17] - **Clinical Data**: Over 4,000 subcutaneous injections administered with no instances of PDSS reported, demonstrating both safety and efficacy [8][26] - **Efficacy Results**: Achieved a statistically and clinically meaningful improvement in symptoms across all doses in the Solaris Phase 3 study [8][17] Competitive Landscape - **Comparison with Existing Treatments**: Elanzapin LAI is positioned as a best-in-class option alongside Uzeti, targeting patients inadequately controlled on oral medications or other LAIs [10][11] - **Market Dynamics**: Anticipated quicker utilization and broader adoption of LAIs, with Elanzapin LAI expected to fulfill a significant treatment gap [12][32] Regulatory and Development Insights - **FDA Engagement**: Ongoing positive discussions with the FDA regarding the safety and efficacy data, with confidence in a favorable label for Elanzapin LAI [26][75] - **Lifecycle Management**: Potential for expanding indications to include bipolar disorder, building a comprehensive franchise around Elanzapin [27][32] Financial Projections - **Revenue Expectations**: Projected peak revenue for the Elanzapin franchise between $1.5 billion and $2 billion, with potential for higher sales based on historical performance of oral Elanzapin [51][70] - **Market Penetration**: Anticipated strong uptake in Europe due to higher existing usage of Elanzapin and LAIs [70][51] Additional Considerations - **Patient Journey**: Understanding the complexities of the patient journey in schizophrenia treatment is crucial for effective intervention and market strategy [12][13] - **Weight Management**: Weight gain associated with Elanzapin is manageable, with strategies in place to mitigate this risk through lifestyle interventions and potential co-prescriptions [37][39] Conclusion - **Strategic Positioning**: Teva is well-positioned to address significant unmet needs in schizophrenia treatment with the launch of Elanzapin LAI, leveraging its established neuroscience legacy and robust clinical data [3][82] - **Future Outlook**: The company expresses optimism about the potential impact of Elanzapin LAI on patient care and market dynamics, with a strong commitment to advancing treatment options in the psychiatric space [82][83]

Core Viewpoint - A new type of injectable nanobody derived from llama antibodies has been developed, offering a potential new treatment avenue for schizophrenia with fewer side effects [1] Summary by Sections Research Findings - The new nanobody specifically activates glutamate receptors, which are key receptors in the brain associated with schizophrenia, potentially improving cognitive impairments that current treatments do not adequately address [1] - The efficacy of the nanobody has been validated in two animal models, showing significant improvement in cognitive abilities of mice with cognitive impairments, with effects lasting over a week post-injection [1] Administration and Safety - The nanobody can be administered via peripheral injection methods such as intravenous or intramuscular routes, and it is biodegradable with minimal side effects [1] Future Directions - Clinical studies are needed to confirm the effectiveness of this treatment approach, and similar therapies may be applicable to other neurological disorders [1]